IDP-108

DRUG2 trials

Sponsors

Dow Pharmaceutical Sciences

Conditions

Onychomycosis

Phase 3

The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

CompletedNCT01007708

Dow Pharmaceutical SciencesOnychomycosis

Start: 2009-11-30End: 2011-12-31Updated: 2012-06-22

Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

CompletedNCT01008033

Dow Pharmaceutical SciencesOnychomycosis

Start: 2009-11-30End: 2011-12-31Updated: 2012-06-22

Related Papers

Efficacy and Safety of Topical Efinaconazole 10% for Onychomycosis: Pooled Phase 3 Trials by Race

SKIN The Journal of Cutaneous Medicine2026-03-10

Topical Efinaconazole 10% for Onychomycosis: Pooled Phase 3 Analysis in White, Black, and Asian Participants.

2026-01-01

Review of the Clinical Efficacy and Safety of Efinaconazole 10% Topical Solution for Onychomycosis Across Subgroups

SKIN The Journal of Cutaneous Medicine2025-11-10

Efficacy and Safety of Efinaconazole 10% Topical Solution for Treatment of Onychomycosis in Older Adults: A Post Hoc Analysis of Two Phase 3 Randomised Trials

Mycoses2025-05-014 citations

Efficacy and Safety of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Older Adults

SKIN The Journal of Cutaneous Medicine2025-03-17